SCENTpart 3. Acute effects on smellprints of chemotherapy in patients with lung cancer.
Suspended
- Conditions
- electronic nosesmell-printexhaled breathlung cancerchemotherapy
- Registration Number
- NL-OMON27548
- Lead Sponsor
- MCL, Leeuwarden
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Not specified
- Target Recruitment
- 75
Inclusion Criteria
1. Informed consent is obtained;
2. newly diagnosed adenocarcinoma or squamous cell carcinoma stage IIIA, IIIB or IV or small cell lung cancer);
Exclusion Criteria
1. Previous chemotherapy;
2. unable to evaluate response with the RECIST criteria;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to investigate whether the eNose can discriminate the smellprints obtained before and after 1 cycle of chemotherapy in patients with specific histological types of lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma and SCLC).<br>
- Secondary Outcome Measures
Name Time Method The secondary objectives are: <br /><br>1. To investigate whether the eNose can discriminate between the baseline smellprints of patients with different histological types of lung cancer (NSCLC: adenocarcinoma, squamous cell carcinoma and SCLC);<br /> <br>2. To investigate whether the pre-chemotherapy smellprint is related to: <br /><br>a. the stage of the disease according to the stage grouping of the Mountain classification (NSCLC) [21] or division into LD or ED (SCLC) [2];<br /><br>b. metabolic activity of the disease as assessed by Standard Uptake Value (SUV) on PET-CT scan;<br /><br>3. To investigate whether the potential change in smellprint after 1 cycle of chemotherapy is related to tumour response (determined after the second cycle of chemotherapy) according to the RECIST criteria. <br>